Thechronic obstructive pulmonary disease(COPD) market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations(LABA/ICSFDCs) toward LABA/long-acting muscarinic antagonist (LAMA) FDCs and even LABA/LAMA/ICSFDCs, but current and emerging generics will have a significant impact on this trend. Some branded generic and generic LABA/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the near future; because cost remains a significant driver, we expect competition from these generics to affect the uptake of both LABA/LAMA and LABA/LAMA/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease, and the development of novel drug classes continues.

QUESTIONS ANSWERED

  • How will markets react to the launch / uptake of generic LABA/ICSFDCs and tiotropium? Will there be significant country-to-country differences in uptake of these generics?
  • Will LABA/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICSFDCs threaten these agents?
  • What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?
  • Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Key Findings
    • Key Updates
      • COPD Webinar: Impact of Changing Perceptions of ICSs
      • COPD Webinar: Impact of Changing Perceptions of ICSs
      • November 2019
      • September 2019
      • May 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Chronic Obstructive Pulmonary Disease?
        • What Factors Are Constraining the Market for Chronic Obstructive Pulmonary Disease?
      • Drug-Class-Specific Trends
        • Long-Acting Muscarinic Antagonists
        • Long-Acting Beta2 Agonist/Inhaled Corticosteroid Fixed-Dose Combinations
        • Long-Acting Beta2 Agonist/Long-Acting Muscarinic Antagonist FDCs
        • Long-Acting Beta2 Agonist/Long-Acting Muscarinic Antagonist/Inhaled Corticosteroid FDCs
        • Long-Acting Beta 2 Agonists
        • Nebulized PDE3/4 Inhibitors
        • Short-Acting Bronchodilators
        • IL-4/IL-13 Inhibitors
    • Forecast
      • Market Forecast Assumptions - COPD 2018-2028 - October 2019
      • Market Forecast Dashboard - COPD 2018-2028 - October 2019
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Disease Progression
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases: GOLD-Defined or Spirometry-Negative
        • Diagnosed Prevalent Cases of COPD
        • Diagnosed Prevalent Cases of COPD by Severity
        • Drug-Treated Cases of COPD
        • Acute Exacerbations of Chronic Obstructive Pulmonary Disease
        • Eosinophilic Chronic Obstructive Pulmonary Disease
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • LAMAs
        • LABAs
        • LABA/ICS FDCs
        • LABA/LAMA FDCs
        • LABA/LAMA/ICS FDCs
        • Oral PDE4 Inhibitors
        • Short-Acting Bronchodilators
        • SABA/SAMA FDCs
        • Methylxanthines
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Chronic Obstructive Pulmonary Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • IL-4 / IL-13 Inhibitors
        • LABA/LAMA/ICS FDCs
        • Nebulized PDE3/4 Inhibitors
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in COPD
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • COPD Bibliography

Author(s): Mohit Nasa, MBA; Stephanie Niquita

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis. He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.

Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.


Related Reports

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 1 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Salmeterol/Fluticasone Generic Wave 1 (US)

Coming Soon – May 2019 MARKET OUTLOOK Mylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable g...

View Details

Chronic Obstructive Pulmonary Disease | Current Treatment | Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (

View Details